Organogenesis (ORGO) Receives Buy Rating from BTIG Research

BTIG Research reissued their buy rating on shares of Organogenesis (NASDAQ:ORGO) in a report published on Sunday morning, AnalystRatings.com reports. The firm currently has a $12.00 price objective on the stock.

“We maintain our Buy rating and $12 PT on shares of ORGO following 1Q19 results. ORGO topped expectations across the board, with rev. of $57.1M beating BTIG/Consensus estimates of $50.6M/$52.6M bolstered by strength in PuraPly and Surgical & Sports Medicine (S&SM). FY19 guidance was raised by ~$2M (at the midpoint) ($248M-$259M to $249M-$262M) on the back of improved expectations in Surgical & Sports Medicine ($29.5M- $31.0M to $30M-$33M) and despite mfg. issues related to Affinity. We view guidance as a reflection of conservatism but confidence in underlying business fundamentals from increased rep growth, account growth, and further account penetration.”,” the firm’s analyst commented.

Other equities research analysts have also issued reports about the company. SunTrust Banks started coverage on Organogenesis in a research report on Thursday, April 11th. They issued a buy rating and a $11.00 price target for the company. Credit Suisse Group started coverage on Organogenesis in a research report on Thursday, May 2nd. They issued an outperform rating and a $9.00 price target for the company. CIBC began coverage on Organogenesis in a research report on Wednesday, April 17th. They issued an outperform rating and a $11.00 price target for the company. Finally, Oppenheimer began coverage on Organogenesis in a research report on Wednesday, April 17th. They issued an outperform rating and a $11.00 price objective for the company. Five research analysts have rated the stock with a buy rating, Organogenesis currently has an average rating of Buy and an average target price of $10.80.

ORGO stock opened at $7.09 on Friday. Organogenesis has a 1 year low of $6.28 and a 1 year high of $310.90.

Organogenesis (NASDAQ:ORGO) last posted its quarterly earnings results on Friday, May 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.05). The firm had revenue of $57.12 million during the quarter, compared to analyst estimates of $55.12 million. On average, sell-side analysts anticipate that Organogenesis will post -0.24 EPS for the current fiscal year.

A number of institutional investors have recently modified their holdings of the stock. BlackRock Inc. purchased a new position in Organogenesis in the first quarter worth approximately $510,000. Charles Schwab Investment Management Inc. purchased a new position in Organogenesis in the first quarter worth approximately $475,000. California Public Employees Retirement System purchased a new position in Organogenesis in the first quarter worth approximately $202,000. Northern Trust Corp purchased a new position in Organogenesis in the first quarter worth approximately $131,000. Finally, Citigroup Inc. purchased a new position in Organogenesis in the first quarter worth approximately $41,000. Institutional investors own 0.08% of the company’s stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types.

Recommended Story: Price to Earnings Ratio (PE) Basics

Analyst Recommendations for Organogenesis (NASDAQ:ORGO)

Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.